KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Other Accumulated Expenses (2016 - 2025)

Pacific Biosciences Of California has reported Other Accumulated Expenses over the past 15 years, most recently at $2.0 million for Q4 2025.

  • Quarterly results put Other Accumulated Expenses at $2.0 million for Q4 2025, down 37.0% from a year ago — trailing twelve months through Dec 2025 was $2.0 million (down 37.0% YoY), and the annual figure for FY2025 was $2.0 million, down 37.0%.
  • Other Accumulated Expenses for Q4 2025 was $2.0 million at Pacific Biosciences Of California, up from $1.0 million in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for PACB hit a ceiling of $8.3 million in Q4 2023 and a floor of $783000.0 in Q3 2024.
  • Median Other Accumulated Expenses over the past 5 years was $4.6 million (2022), compared with a mean of $4.3 million.
  • Biggest five-year swings in Other Accumulated Expenses: soared 115.55% in 2021 and later plummeted 84.85% in 2024.
  • Pacific Biosciences Of California's Other Accumulated Expenses stood at $5.8 million in 2021, then increased by 25.59% to $7.2 million in 2022, then increased by 15.11% to $8.3 million in 2023, then tumbled by 61.28% to $3.2 million in 2024, then plummeted by 37.0% to $2.0 million in 2025.
  • The last three reported values for Other Accumulated Expenses were $2.0 million (Q4 2025), $1.0 million (Q3 2025), and $2.6 million (Q2 2025) per Business Quant data.